Chugai Pharmaceutical Co Ltd – Lobbying Governance & Transparency

Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:

Lobbying Governance

Overall Assessment	Analysis	Score
Limited	Chugai Pharmaceutical discloses that it "has a public commitment or position statement to conduct [its] engagement activities in line with the goals of the Paris Agreement" and explains that climate-related engagement is framed by "mid-term environmental goals… approved by the Management Committee" with progress "regularly report[ed]" to senior management, indicating some high-level oversight. The company further notes that its Board "receiv[es] regular quarterly reports" and that issues are "thoroughly discussed by the Sustainability Committee… then brought up to the Executive Committee for deliberation and reported to the Board of Directors," showing that identified governance bodies monitor general climate matters. However, the disclosure centres on internal climate-strategy management rather than the governance of policy advocacy: there is no description of processes to review or align direct lobbying positions, no reference to assessing trade-association advocacy, and no named individual or procedure specifically tasked with ensuring lobbying consistency with climate commitments. Therefore, while the public commitment to align external engagement with the Paris Agreement and the mention of board-level climate oversight indicate limited governance, the company does not disclose a dedicated framework for managing or auditing lobbying activities. View Sources	D

Overall Assessment

Analysis

Score

Limited

Chugai Pharmaceutical discloses that it "has a public commitment or position statement to conduct [its] engagement activities in line with the goals of the Paris Agreement" and explains that climate-related engagement is framed by "mid-term environmental goals… approved by the Management Committee" with progress "regularly report[ed]" to senior management, indicating some high-level oversight. The company further notes that its Board "receiv[es] regular quarterly reports" and that issues are "thoroughly discussed by the Sustainability Committee… then brought up to the Executive Committee for deliberation and reported to the Board of Directors," showing that identified governance bodies monitor general climate matters. However, the disclosure centres on internal climate-strategy management rather than the governance of policy advocacy: there is no description of processes to review or align direct lobbying positions, no reference to assessing trade-association advocacy, and no named individual or procedure specifically tasked with ensuring lobbying consistency with climate commitments. Therefore, while the public commitment to align external engagement with the Paris Agreement and the mention of board-level climate oversight indicate limited governance, the company does not disclose a dedicated framework for managing or auditing lobbying activities.

View Sources

Lobbying Transparency

Overall Assessment	Analysis	Score
Limited	Chugai Pharmaceutical provides only limited insight into its climate-policy lobbying. Through its membership in the Japan Climate Initiative the company signals support for policy areas such as a halving of national emissions by 2030, net-zero emissions by 2050, a 40-50 % renewable-energy share in 2030 and the phase-out of coal-fired power generation, but it does not name any specific bills, regulations or government programmes it has attempted to influence. The sole mechanism disclosed is indirect engagement via this multi-stakeholder network; there is no description of direct actions such as meetings, submissions or correspondence, nor are individual government ministries or officials identified as targets. Likewise, while the company endorses broad climate goals, it does not spell out the precise legislative changes, amendments or financial measures it seeks. As a result, the disclosures offer only a high-level picture of intent and provide little detail on actual lobbying activities, channels or concrete policy outcomes sought.	D